General Information of Drug (ID: DMU2H4K)

Drug Name
STAUROSPORINONE Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3815
TTD Drug ID
DMU2H4K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [1]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [1]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [1]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [7]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [9]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [10]
PMID28460551-Compound-3 DMA1FRM N. A. N. A. Patented [11]
ISIS 3521 DMZFS69 N. A. N. A. Discontinued in Phase 2 [12]
BALANOL DMDLN9E N. A. N. A. Terminated [13]
RO-320432 DMFZ1YW N. A. N. A. Terminated [14]
LY-317644 DMM20PI N. A. N. A. Terminated [15]
Acteoside DM0YHKB Nephritis GB40 Terminated [16]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [17]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NKP-1339 DM5AWK1 Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [19]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [19]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [19]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [19]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [19]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [19]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [19]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [19]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [20]
SB 235699 DMNH8XU Psoriasis vulgaris EA90 Discontinued in Phase 1 [20]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [1]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [1]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [1]
KN-62 DMLZ89P Discovery agent N.A. Investigative [1]
Ro31-8220 DMDJLF0 Discovery agent N.A. Investigative [1]
KT-5720 DM9J50F Discovery agent N.A. Investigative [1]
L-779450 DM51B74 Discovery agent N.A. Investigative [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TENELLONE A DM1S209 Discovery agent N.A. Investigative [22]
TENELLONE B DM9ZVJ7 Discovery agent N.A. Investigative [22]
ARC-1028 DM0KDTG Discovery agent N.A. Investigative [23]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [24]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [24]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [25]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [20]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [24]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [19]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [19]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [19]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [19]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [26]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [26]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [26]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [3]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [27]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [28]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [29]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [30]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [26]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [29]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [31]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [32]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [33]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [34]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [35]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [36]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [37]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [38]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [39]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting MAP kinase p38 (MAPK12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SM-101 DMFX9O6 Idiopathic thrombocytopenic purpura 3B64.10 Approved (orphan drug) [41]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [42]
ARRY-797 DMJ48AB Dilated cardiomyopathy BC43.0 Phase 2 [43]
KC706 DMBX6C7 Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [44]
SB 235699 DMNH8XU Psoriasis vulgaris EA90 Discontinued in Phase 1 [45]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [1]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [1]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [1]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M2698 DM3PVBJ Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
NNI-362 DMPCV65 Alzheimer disease 8A20 Phase 1 [46]
PF-4708671 DMO0892 Ulcerative colitis DD71 Clinical trial [47]
PMID27410995-Compound-Figure3c DMDQMZT N. A. N. A. Patented [48]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 DM6O2Q9 N. A. N. A. Patented [48]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [1]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [49]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [6]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [1]
KN-62 DMLZ89P Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [50]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [51]
Methotrexate DM2TEOL Anterior urethra cancer Approved [52]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [54]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [55]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [56]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [57]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [58]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [60]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [61]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [62]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [63]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [64]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [65]
Amiloride DMRTSGP Congestive heart failure BD10 Approved [66]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [67]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [64]
Paclitaxel DMLB81S Breast carcinoma Approved [68]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
cGMP-dependent protein kinase (cGK) TTZC6DR KGP1_HUMAN; KGP2_HUMAN Inhibitor [2]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [1]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [1]
MAP kinase p38 (MAPK12) TTYT93M MK12_HUMAN Inhibitor [1]
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [1]
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [1]
Ribosomal protein S6 kinase beta-1 (S6K1) TTG0U4H KS6B1_HUMAN Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]
Stress-activated protein kinase 2b (p38 beta) TT73U6C MK11_HUMAN Inhibitor [1]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-phosphoinositide-dependent protein kinase 1 (PDPK1) OTT09ZVP PDPK1_HUMAN Gene/Protein Processing [1]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Gene/Protein Processing [1]

References

1 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
2 Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 3(10):1959-1964 (1993).
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 National Cancer Institute Drug Dictionary (drug id 596693).
5 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
6 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
7 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
8 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
9 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
10 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
11 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
12 Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
13 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
14 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
15 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
16 Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
17 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
19 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
20 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
21 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
22 Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity. J Nat Prod. 2005 Apr;68(4):611-3.
23 Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhi... J Med Chem. 2009 Jan 22;52(2):308-21.
24 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
25 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
30 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
31 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
32 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
33 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
34 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
35 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
36 Company report (Neurim Pharmaceuticals)
37 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
38 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
39 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
40 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
41 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
42 P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
43 Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
44 KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
45 Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
46 Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
47 Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
48 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
49 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
50 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
51 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
52 Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
53 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
54 Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
55 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
56 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
57 Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci. 2009 Sep;111(1):120-30. doi: 10.1093/toxsci/kfp136. Epub 2009 Jun 18.
58 ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem. 2006 Sep 29;281(39):28764-71. doi: 10.1074/jbc.M604392200. Epub 2006 Aug 3.
59 Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem. 2012 Apr 20;287(17):14289-300. doi: 10.1074/jbc.M112.353201. Epub 2012 Mar 1.
60 Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
61 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
62 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
63 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
64 Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
65 Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):117-27.
66 Role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride. J Cell Biochem. 2005 Oct 1;96(2):376-89. doi: 10.1002/jcb.20512.
67 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
68 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.